Larimar Therapeutics (LRMR) News Today $2.34 +0.07 (+2.86%) As of 09:55 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Larimar Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Larimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Has Average Price Target of $10.33 According to AnalystsOctober 20 at 2:15 AM | americanbankingnews.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Now Rated "Buy" by Wall Street AnalystsOctober 20 at 2:13 AM | marketbeat.comLarimar Therapeutics (NASDAQ:LRMR) Shares Down 0.3% - Should You Sell?October 16, 2026 | marketbeat.com3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead (LRMR)Inventiva, Larimar Therapeutics, and Ascentage Pharma face key drug-development milestones, with analysts assigning Buy ratings and triple-digit upside price targets to all three biotech stocks.October 10, 2026 | marketbeat.comLarimar Therapeutics Names John Harlow As President And COOSeptember 30, 2026 | rttnews.comLarimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating OfficerSeptember 29, 2026 | globenewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Neogen (NEOG), Larimar Therapeutics (LRMR) and Sagimet Biosciences, Inc. Class A (SGMT)September 29, 2026 | theglobeandmail.comLarimar Therapeutics, Inc. (NASDAQ:LRMR) Stock Has Average Price Target of $11.86 According to BrokeragesSeptember 25, 2026 | marketbeat.comLarimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in PlaySeptember 3, 2026 | tipranks.comLarimar’s Phase 3 Friedreich’s Ataxia Trial Puts Nomlabofusp in the Investor SpotlightAugust 21, 2026 | tipranks.comRegulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for NomlabofuspAugust 7, 2026 | theglobeandmail.comLarimar Therapeutics Reports Second Quarter 2026 Financial and Business UpdateAugust 4, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 23, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 21, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 16, 2026 | prnewswire.comLarimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp TherapyJuly 16, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 14, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 9, 2026 | prnewswire.comLarimar Therapeutics (NASDAQ:LRMR) Director Buys 50,000 SharesJuly 9, 2026 | insidertrades.comLRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000July 8, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 7, 2026 | globenewswire.comHere’s What Citi Thinks About Larimar Therapeutics (LRMR)July 3, 2026 | finance.yahoo.comLRMR shares hold steady as Wall Street optimism offsets drug safety concernsJuly 2, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 1, 2026 | prnewswire.comLarimar's rare disease push just hit a key inflection point — what investors need to knowJune 29, 2026 | msn.comLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s AtaxiaJune 29, 2026 | finance.yahoo.comLarimar Therapeutics shares drop following clinical update and regulatory filing (LRMR)June 29, 2026 | msn.comLarimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia TranscriptJune 29, 2026 | seekingalpha.comLarimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich's AtaxiaJune 29, 2026 | globenewswire.comLarimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s AtaxiaJune 26, 2026 | markets.businessinsider.comLarimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's AtaxiaJune 26, 2026 | globenewswire.comJP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight RecommendationMay 28, 2026 | msn.comLarimar Therapeutics Reports First Quarter 2026 Financial and Business UpdateMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR)May 2, 2026 | theglobeandmail.comLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s AtaxiaApril 30, 2026 | markets.businessinsider.comLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's AtaxiaApril 30, 2026 | globenewswire.comWedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13March 27, 2026 | finance.yahoo.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 19, 2026 | globenewswire.com2 Breakout Stocks to Buy ImmediatelyMarch 8, 2026 | investorplace.comLarimar Therapeutics to Participate in Upcoming Investor Conferences in MarchMarch 4, 2026 | globenewswire.comLarimar Therapeutics price target raised to $12 from $11 at WedbushMarch 4, 2026 | finance.yahoo.comInsider Buying: Larimar Therapeutics (NASDAQ:LRMR) Director Buys $25,000,000.00 in StockMarch 3, 2026 | insidertrades.comLarimar Therapeutics: Deerfield entities buy $25m in stockMarch 3, 2026 | investing.comLarimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?February 28, 2026 | finance.yahoo.comLarimar Therapeutics stock falls 8% on upsized $100 million offeringFebruary 27, 2026 | in.investing.comLarimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingFebruary 25, 2026 | globenewswire.comLarimar Therapeutics Announces Proposed $75 Million Underwritten Public OfferingFebruary 25, 2026 | globenewswire.comLarimar Therapeutics stock surges on FDA breakthrough statusFebruary 24, 2026 | za.investing.comWhy did Larimar Therapeutics’ stock surge over 30% pre-market today?February 24, 2026 | msn.comLarimar surges on FDA breakthrough status for lead assetFebruary 24, 2026 | msn.com Larimar Therapeutics Media Mentions By Week Larimar Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LRMR News Sentiment▼0.830.47▲Average Healthcare News Sentiment Larimar Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LRMR Articles This Week▼33▲LRMR Articles Average Week Larimar Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers3+200%Searches1Page Views5,139-12% Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ArriVent BioPharma News MoonLake Immunotherapeutics News Aktis Oncology News Kura Oncology News Corvus Pharmaceuticals News Alumis News Verastem News Geron News Adlai Nortye News Sana Biotechnology News News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Larimar Therapeutics dated 10/20/2026. From Our PartnersTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
